Omeros (OMER) Free Cash Flow (2010 - 2026)
Omeros (OMER) posted Free Cash Flow of -$14.5 million for Q1 2026, up 63.59% sequentially from -$39.8 million in Q4 2025, and up 59.57% YoY from -$9.1 million in Q1 2025.
Omeros (OMER) Free Cash Flow (2010 - 2026) Analysis & Trends
Omeros has reported Free Cash Flow for 17 years, with the latest figure at -$14.5 million in Q1 2026.
- Quarterly Free Cash Flow rose 59.57% year-over-year to -$14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$94.8 million (up 33.72% YoY) and the FY2025 annual result came in at -$116.2 million, up 22.02% from the prior year.
- Free Cash Flow climbed to -$14.5 million in Q1 2026 per OMER's latest filing, from -$39.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $174.5 million in Q1 2023 and troughed at -$46.1 million in Q2 2024.
- A 5-year average of -$17.2 million and a median of -$29.0 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 1248.81% in 2023, then sank 123.97% in 2024.
- Over 5 years, Free Cash Flow stood at -$25.4 million in 2022, then tumbled by 37.6% to -$34.9 million in 2023, then gained by 16.99% to -$29.0 million in 2024, then slumped by 37.36% to -$39.8 million in 2025, then surged by 63.59% to -$14.5 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$14.5 million, -$39.8 million, and -$18.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 4.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.10 Mn |
| Jun 30, 2026 | 4.10 Mn |
| Mar 31, 2026 | -14.51 Mn |
| Mar 31, 2026 | -14.51 Mn |
| Dec 31, 2025 | -39.84 Mn |
| Dec 31, 2025 | -39.84 Mn |
| Sep 30, 2025 | -18.48 Mn |
| Sep 30, 2025 | -18.48 Mn |
| Jun 30, 2025 | -21.95 Mn |
| Jun 30, 2025 | -21.95 Mn |
| Mar 31, 2025 | -35.88 Mn |
| Mar 31, 2025 | -35.88 Mn |
| Dec 31, 2024 | -29.01 Mn |
| Dec 31, 2024 | -29.01 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Jun 30, 2024 | -46.07 Mn |
| Jun 30, 2024 | -46.07 Mn |
| Mar 31, 2024 | -41.84 Mn |
| Mar 31, 2024 | -41.84 Mn |